Leading-edge technologies in the fight against cancer
We are a next generation radiopharmaceutical company, taking cancer head on.
Thank you! Your submission has been received!
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance
POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that the closing conditions, including Hart-Scott-Rodino antitrust clearance, have been met for the previously announced agreements with Lantheus Holdings Inc. (NASDAQ: LNTH). Under the terms of the agreements, POINT will receive the initial $260 million in upfront payments from Lantheus in the upcoming week.